Literature DB >> 28132948

Added value of hepcidin quantification for the diagnosis and follow-up of anemia-related diseases.

Thibaud Lefebvre1, Sigismond Lasocki2, Martine Fénéant-Thibault3, Pierre-Jean Lamy4, Séverine Cunat5, Madeleine Ropert-Bouchet6, Patricia Aguilar-Martinez5, Sylvain Lehmann7, Constance Delaby7.   

Abstract

Iron homeostasis is based on a strict control of both intestinal iron absorption and iron recycling through reticulo-endothelial system. Hepcidin controls the iron fluxes in order to maintain sufficient iron levels for erythropoietic activities, hemoproteins synthesis or enzymes function, but also to limit its toxic accumulation throughout the body. Hepcidin expression is regulated by various stimuli: inflammation and iron stimulate the production of the peptide, while anemia, erythropoiesis and hypoxia repress its production. Regulation of hepcidin expression is not so simple in complex pathological situations such as hemolytic anemia, cancer or chronic inflammation. Serum hepcidin quantification in association with the diagnostic tests currently available is quite promising for the diagnosis or the follow-up of anemia in those conditions. This study is part of the working group « Clinical interests of hepcidin quantification » of the Société française de biologie clinique.

Entities:  

Keywords:  anemia; hepcidin; inflammation; iron

Mesh:

Substances:

Year:  2017        PMID: 28132948     DOI: 10.1684/abc.2016.1208

Source DB:  PubMed          Journal:  Ann Biol Clin (Paris)        ISSN: 0003-3898            Impact factor:   0.459


  2 in total

1.  The prognostic impact of decreased pretreatment haemoglobin level on the survival of patients with lung cancer: a systematic review and meta-analysis.

Authors:  Yaqi Huang; Siqi Wei; Nan Jiang; Lijuan Zhang; Siyuan Wang; Xiaona Cao; Yue Zhao; Peiguo Wang
Journal:  BMC Cancer       Date:  2018-12-10       Impact factor: 4.430

2.  Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.

Authors:  Sophie Park; Olivier Kosmider; Frédéric Maloisel; Bernard Drenou; Nicolas Chapuis; Thibaud Lefebvre; Zoubida Karim; Hervé Puy; Anne Sophie Alary; Sarah Ducamp; Frédérique Verdier; Cécile Bouilloux; Alice Rousseau; Marie-Christine Jacob; Agathe Debliquis; Agnes Charpentier; Emmanuel Gyan; Bruno Anglaret; Cecile Leyronnas; Selim Corm; Borhane Slama; Stephane Cheze; Kamel Laribi; Shanti Amé; Christian Rose; Florence Lachenal; Andrea Toma; Gian Matteo Pica; Martin Carre; Frédéric Garban; Clara Mariette; Jean-Yves Cahn; Mathieu Meunier; Olivier Herault; Pierre Fenaux; Orianne Wagner-Ballon; Valerie Bardet; Francois Dreyfus; Michaela Fontenay
Journal:  Haematologica       Date:  2018-10-04       Impact factor: 9.941

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.